About 6 results
Open links in new tab
  2. The company is preparing for two key drug approvals in January 2025: suzetrigine for acute pain and a new triple combination therapy (vanza triple) for cystic fibrosis. Suzetrigine, a non-opioid acute pain medication, is generating particular interest among analysts.

    Vertex Pharmaceuticals' SWOT analysis: strong CF franchise fuels ...

    in.investing.com/news/swot-analysis/vertex-pharmaceuticals-swot-analysis-strong-cf-franchise-fuels-pipeline-stock-growth-93CH-4632464
    in.investing.com/news/swot-analysis/vertex-pharmaceuticals-swot-analysis-stro…
    Was this helpful?
  3. Markets Insider
    https://markets.businessinsider.com › news › stocks › ...

    Vertex Pharmaceuticals Incorporated (VRTX ... - Markets Insider

    Tags:
    Vertex Pharmaceuticals
    Shareholder
  4. People also ask
    Does Vertex Pharmaceuticals (VRTX) dominate the cystic fibrosis treatment market?
    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a promising pipeline of therapies for other serious diseases.

    Vertex Pharmaceuticals' SWOT analysis: strong CF franchise fuels pipelin…

    msn.com
    Will vertex expand its CF treatment pipeline in 2025?
    While CF treatments drive current growth, Vertex's pipeline holds significant potential for future expansion. The company is preparing for two key drug approvals in January 2025: suzetrigine for acute pain and a new triple combination therapy (vanza triple) for cystic fibrosis.

    Vertex Pharmaceuticals' SWOT analysis: strong CF franchise fuels pipelin…

    msn.com
    Will vertex's new drug be a blockbuster?
    Vertex is headquartered in Boston. This week, the FDA is expected to release its approval decision for the non-opioid painkiller made by Vertex Pharmaceuticals Inc. The company that can capture the pain medicine market could hit a windfall. But it's still uncertain whether Vertex's new drug will be the blockbuster the company believes it can be.

    Vertex is hoping for 'historic' non-opioid painkiller approval. It might no…

    bizjournals.com
    Will the FDA approve Vertex Pharmaceuticals Inc's acute-pain medicine?
    The FDA is to decide by Jan. 30 whether to approve Vertex Pharmaceuticals Inc.'s acute-pain medicine. Vertex is headquartered in Boston. This week, the FDA is expected to release its approval decision for the non-opioid painkiller made by Vertex Pharmaceuticals Inc. The company that can capture the pain medicine market could hit a windfall.

    Vertex is hoping for 'historic' non-opioid painkiller approval. It might no…

    bizjournals.com
    Why has David Risinger rated Vertex Pharmaceuticals a buy?
    David Risinger has given his Buy rating due to a combination of factors surrounding Vertex Pharmaceuticals’ innovations in pain management. The introduction of suzetrigine, a NaV1.8 inhibitor, is particularly promising because of its potential to address acute pain without relying on opioids.

    Vertex Pharmaceuticals’ Suzetrigine: A Promising Opioid Alternative in P…

    markets.businessinsider.com
    Is vertex a good stock to buy now?
    The majority of analysts maintain positive ratings on Vertex stock, though price targets vary. As of January 27, 2025, Piper Sandler has set the highest price target at $533, while maintaining an Overweight rating.

    Vertex Pharmaceuticals' SWOT analysis: strong CF franchise fuels pipelin…

    msn.com
    Feedback
  5. Investing.com Deutsch
    https://de.investing.com › news › swot-analysis › swot...Translate this result

    SWOT-Analyse von Vertex Pharmaceuticals: Starkes CF-Franchise …

  6. Investing.com Español
    https://es.investing.com › news › swot-analysis › ...Translate this result

    Análisis DAFO de Vertex Pharmaceuticals: la sólida franquicia de la ...

  7. EIN Presswire
    https://www.einnews.com › pr_news

    Sanger Sequencing Market to Reach $12.35 Billion by 2032, …

    Tags:
    Sanger sequencing
    Compound annual growth rate
  9. Investing.com Canada
    https://ca.investing.com › news › analyst-ratings

    BTIG sets $41 target for Arcturus stock, cites strong prospects

  10. MENAFN.COM
    https://menafn.com

    Sanger Sequencing Market To Reach $12.35 Billion By 2032, …

    Tags:
    Sanger sequencing
    Compound annual growth rate
  11. openPR.com
    https://www.openpr.com › news › advancing...

    Advancing Respiratory Care: Growth Opportunities in Pulmonary